Search results for "Type I"

showing 10 items of 966 documents

Cumulative incidence rates of the mucopolysaccharidoses in Germany

2005

In order to estimate the cumulative incidence rates of the mucopolysaccharidoses (MPS) in Germany, a retrospective epidemiological survey covering the period between 1980 and 1995 was implemented. Multiple ascertainment sources were used to identify affected patients. A prevalence of approximately 0.69 cases per 100,000 births was obtained for MPS I (Hurler phenotype). Within the study period, 4 patients with Hurler/Scheie phenotype and 7 cases with Scheie disease were detected. The cumulative incidence for MPS II (Hunter syndrome) was estimated as 0.64 cases per 100,000 births (1.3 cases per 100,000 male live births); that for MPS III (Sanfilippo syndrome types A, B and C) as 1.57 cases in…

Malecongenital hereditary and neonatal diseases and abnormalitiesPediatricsmedicine.medical_specialtyMorquio syndromeGenotypeTurkeyMucopolysaccharidosisMucopolysaccharidosis type IIIGermanyGeneticsmedicineHumansCumulative incidenceMucopolysaccharidosis type IIskin and connective tissue diseasesGenetics (clinical)Retrospective StudiesSanfilippo syndromebusiness.industryIncidenceIncidence (epidemiology)nutritional and metabolic diseasesHunter syndromeMucopolysaccharidosesHospital Recordsbeta-Galactosidasemedicine.diseasePhenotypeFemalebusinessJournal of Inherited Metabolic Disease
researchProduct

Receptor identification and physiological characterisation of glucagon-like peptide-2 in the rat heart.

2010

Abstract Background and aims The anorexigenic glucagon-like peptide (GLP)-2 is produced by intestinal L cells and released in response to food intake. It affects intestinal function involving G-protein-coupled receptors. To verify whether GLP-2 acts as a cardiac modulator in mammals, we analysed, in the rat heart, the expression of GLP-2 receptors and the myocardial and coronary responses to GLP-2. Methods and results GLP-2 receptors were detected on ventricular extracts by quantitative real-time polymerase chain reaction (Q-RT-PCR) and Western blotting. Cardiac GLP-2 effects were analysed on Langendorff perfused hearts. Intracellular GLP-2 signalling was investigated on Langendorff perfuse…

Maleendocrine systemmedicine.medical_specialtyCardiotonic AgentsNitric Oxide Synthase Type IIIMAP Kinase Signaling SystemG proteinEndocrinology Diabetes and MetabolismBlotting WesternMedicine (miscellaneous)Enzyme-Linked Immunosorbent AssayStimulationIn Vitro TechniquesBiologyReal-Time Polymerase Chain Reactionglucagon-like peptides-2 gut peptides cardiac performanceSettore BIO/09 - FisiologiaGlucagon-Like Peptide-1 Receptorchemistry.chemical_compoundInternal medicineCyclic AMPCyclic GMP-Dependent Protein KinasesGlucagon-Like Peptide 2Receptors GlucagonmedicineAnimalsCyclic adenosine monophosphatePhosphorylationRats WistarReceptorNutrition and Dieteticsdigestive oral and skin physiologyHeartPeptide FragmentsRatsPhospholambanEndocrinologyGene Expression RegulationchemistryInotropismGlucagon-Like Peptide-2 ReceptorCardiology and Cardiovascular MedicinecGMP-dependent protein kinasehormones hormone substitutes and hormone antagonistsIntestinal L CellsSignal Transduction
researchProduct

Neurochemistry of olivocochlear neurons in the hamster.

2009

The present study was conducted to characterize the superior olivary complex (SOC) of the lower brain stem in the pigmented Djungarian hamster Phodopus sungorus. Using Nissl-stained serial cryostat sections from fresh-frozen brains, we determined the borders of the SOC nuclei. We also identified olivocochlear (OC) neurons by retrograde neuronal tracing upon injection of Fluoro-Gold into the scala tympani. To evaluate the SOC as a putative source of neuronal nitric oxide synthase (nNOS), arginine-vasopressin (AVP), oxytocin (OT), vasoactive intestinal polypeptide (VIP), or pituitary adenylate cyclase-activating polypeptide (PACAP) that were all found in the cochlea, we conducted immunohistoc…

Maleendocrine systemmedicine.medical_specialtyHistologyAuditory PathwaysPhodopusStilbamidinesVasoactive intestinal peptideHamsterNitric Oxide Synthase Type IOlivary NucleusNitric OxideOxytocinEfferent Pathwayschemistry.chemical_compoundInternal medicineCricetinaeNitrergic NeuronsPonsotorhinolaryngologic diseasesmedicineAnimalsNeurotransmitterEcology Evolution Behavior and SystematicsbiologyStaining and LabelingOlivocochlear systembiology.organism_classificationRetrograde tracingImmunohistochemistryCochleaNeuronal tracingPhodopusArginine VasopressinEndocrinologynervous systemchemistrySuperior olivary complexPituitary Adenylate Cyclase-Activating Polypeptidesense organsAnatomyhormones hormone substitutes and hormone antagonistsBiotechnologyAnatomical record (Hoboken, N.J. : 2007)
researchProduct

A nitrergic projection from the superior olivary complex to the inferior colliculus of the rat

2003

The present study was conducted to test whether the ascending auditory projection from the superior olivary complex (SOC) of the brainstem to the inferior colliculus (IC) may use nitric oxide (NO) as a neuroactive compound. We identified olivo-collicular projection neurons in subnuclei of the SOC by retrograde neuronal tracing with Fluoro-Gold (FG) injected into the central nucleus of the IC. Sections containing retrograde labelled neurons were subjected to immunohistochemical incubation in an antiserum directed against the enzyme responsible for NO production in nerve cells, neuronal NO synthase (nNOS). The analysis showed that FG-containing neurons as well as nNOS-immunoreactive neurons w…

Maleinorganic chemicalsInferior colliculusStilbamidinesNitric Oxide Synthase Type IOlivary NucleusNitric OxideRats Sprague-Dawleyotorhinolaryngologic diseasesmedicineAnimalsTrapezoid bodyFluorescent DyesNeuronsAfferent PathwaysStaining and LabelingChemistryAnatomyImmunohistochemistryRetrograde tracingInferior ColliculiSensory SystemsRatsNeuronal tracingmedicine.anatomical_structurenervous systemSuperior olivary complexBrainstemNitric Oxide SynthaseNitrergic NeuronNeuroscienceNucleusHearing Research
researchProduct

Detectable interleukin-9 plasma levels are associated with impaired cardiopulmonary functional capacity and all-cause mortality in patients with chro…

2016

Inflammatory activation plays a pivotal role in chronic heart failure (CHF) through the increased expression of pro-inflammatory cytokines [1]. Decreased plasma levels of Interleukin (IL-) 5, IL-7 and Interferon-γ (IFN-γ) and increased levels of IL-9 have been already described in CHF [2], and a negative correlation was also reported between IL-9 and left ventricular ejection fraction (LVEF) [2]. Yet, there are only limited data exploring the association between cytokines and functional capacity in CHF and their prognostic role [3]; therefore, primary end-point of the current study was to evaluate all-cause mortality according to changes in cytokines plasma levels in CHF patients.  

Malemedicine.medical_specialty030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineCause of DeathmedicineHumansInterleukin 9030212 general & internal medicineInterleukin 6CytokineInterleukin 5Risk stratificationInterleukin 4OutcomeAgedHeart Failurebiologybusiness.industryRisk FactorInterleukin-9Middle Agedmedicine.diseaseChronic heart failurePeak oxygen consumptionInterleukin 10EndocrinologyInterleukin 15Heart failurebiology.proteinCardiologyFemaleChronic heart failure; Cytokines; Interleukin-9; Outcomes; Peak oxygen consumption; Risk stratification; Cardiology and Cardiovascular MedicineCardiology and Cardiovascular MedicinebusinessInterleukin 1 receptor type IHumanInternational journal of cardiology
researchProduct

Management of homozygous familial hypercholesterolaemia in two brothers

2018

Homozygous familial hypercholesterolaemia (HoFH) is a rare, genetic disorder of abnormally high levels of low-density lipoprotein cholesterol (LDL-C) requiring aggressive interventions to retard the evolution of atherosclerotic cardiovascular disease. We treated two brothers (ages 46 years and 47 years) with HoFH with statins, lipoproteinapheresis (LA) and the microsomal triglyceride transfer protein inhibitor lomitapide. Both brothers carried the p.Thr434Arg homozygous LDLR mutation and had childhood total cholesterol levels >700 mg/dL. Inter-LA LDL-C levels remained high; therefore, they were given escalating doses of oral lomitapide (5–10 mg/day). One brother was able to maintain LDL-C l…

Malemedicine.medical_specialty1523030204 cardiovascular system & hematologyMicrosomal triglyceride transfer proteinHyperlipoproteinemia Type II03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRare DiseaseTotal cholesterolInternal medicinelipid disordersmedicineHumans1506030212 general & internal medicineLipoprotein cholesterolcongenital disordersbiologyAtherosclerotic cardiovascular diseasebusiness.industryAnticholesteremic AgentsSiblingsHomozygoteGenetic disorderGeneral MedicineMiddle Agedmedicine.diseaseLomitapideendocrine systemEndocrinologyReceptors LDLchemistryMutationLDL receptorbiology.proteinBenzimidazoleslipids (amino acids peptides and proteins)businessRare diseaseBMJ Case Reports
researchProduct

Combined therapy with insulin and growth hormone in 17 patients with type-1 diabetes and growth disorders.

2013

<b><i>Background/Aim:</i></b> Combined growth hormone (GH) and insulin therapy is rarely prescribed by pediatric endocrinologists. We investigated the attitude of Italian physicians to prescribing that therapy in the case of short stature and type-1 diabetes (T1DM). <b><i>Methods:</i></b> A questionnaire was sent and if a patient was identified, data on growth and diabetes management were collected. <b><i>Results:</i></b> Data from 42 centers (84%) were obtained. Of these, 29 centers reported that the use of combined therapy was usually avoided. A total of 17 patients were treated in 13 centers (GH was started before T1…

Malemedicine.medical_specialtyAdolescentGrowth hormone; Insulin therapy; GH deficiency; Type-1 diabetes; Turner syndromeTurner syndromeEndocrinology Diabetes and Metabolismmedicine.medical_treatmentType-1 diabeteseducationDwarfismTYPE I (INSULIN-DEPENDENT) DIABETES MELLITUSGrowth hormoneSettore MED/38 - Pediatria Generale E SpecialisticaEndocrinologyInsulin resistancePharmacotherapySurveys and QuestionnairesInternal medicineDiabetes mellitusgrowth hormone treatment; TYPE I (INSULIN-DEPENDENT) DIABETES MELLITUSTurner syndromemedicineHumansHypoglycemic AgentsInsulinChildDwarfism PituitaryGrowth hormoneGrowth DisordersGH deficiencyType 1 diabetesHuman Growth Hormonebusiness.industryInsulingrowth hormone treatmentmedicine.diseaseDiabetes Mellitus Type 1EndocrinologyChild PreschoolPediatrics Perinatology and Child HealthInsulin therapyDrug Therapy CombinationFemaleInsulin Resistancebusiness
researchProduct

Hunter disease before and during enzyme replacement therapy.

2011

Mucopolysaccharidosis type II (Hunter disease) is a lysosomal storage disease attributable to X-linked deficiency of the enzyme α-L-iduronate-sulfatase. Because of this deficiency, glycosaminoglycanes accumulate in various tissues and body fluids. We describe three patients representing the broad spectrum of Hunter disease and their response to enzyme replacement therapy. Patient 1 did not manifest central nervous system involvement, patient 2 manifested moderate neurologic disease, and patient 3 had already manifested a severe neurologic course during early infancy. In all patients, improvements in visceral organ size, physical capacity, and gastrointestinal functioning were reported. More…

Malemedicine.medical_specialtyAdolescentmedicine.drug_classAntibioticsCentral nervous systemIduronate SulfataseBiologyGastroenterologyFrameshift mutationYoung AdultDevelopmental NeuroscienceInternal medicinemedicineLysosomal storage diseaseMissense mutationHumansEnzyme Replacement TherapyMucopolysaccharidosis type IIYoung adultChildGlycosaminoglycansMucopolysaccharidosis IIInfant NewbornInfantEnzyme replacement therapyOrgan Sizemedicine.diseaseSurgeryGastrointestinal Tractmedicine.anatomical_structureNeurologyChild PreschoolPediatrics Perinatology and Child HealthNeurology (clinical)Nervous System DiseasesPediatric neurology
researchProduct

A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Pati…

2020

INTRODUCTION Metabolic-associated fatty liver disease is common, with fibrosis the major determinant of adverse outcomes. Population-based screening tools with high diagnostic accuracy for the staging of fibrosis are lacking. METHODS Three independent cohorts, 2 with both liver biopsy and liver stiffness measurements (LSMs, n = 254 and 65) and a population sample (n = 713), were studied. The performance of a recently developed noninvasive algorithm (ADAPT [age, diabetes, PRO-C3 and platelets panel]) as well as aspartate aminotransferase-to-platelet ratio index, fibrosis-4, nonalcoholic fatty liver disease fibrosis score, and LSM was used to stage patients for significant (≥F2) and advanced …

Malemedicine.medical_specialtyBiopsyPopulationGastroenterology03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseasePredictive Value of TestsDiabetes mellitusInternal medicineNonalcoholic fatty liver diseasemedicineDiabetes MellitusHumansAspartate Aminotransferaseseducationeducation.field_of_studyHepatologymedicine.diagnostic_testReceiver operating characteristicbusiness.industryPlatelet CountFatty liverGastroenterologyAge FactorsOdds ratioMiddle Agedmedicine.diseaseCollagen Type III030220 oncology & carcinogenesisLiver biopsyElasticity Imaging Techniques030211 gastroenterology & hepatologyFemalebusinessAlgorithmsBiomarkersThe American journal of gastroenterology
researchProduct

Acetylcholine leads to signal transducer and activator of transcription 1 (STAT-1) mediated oxidative/nitrosative stress in human bronchial epithelia…

2013

AbstractThe induction of nitric oxide synthase (iNOS) expression via the signal transducer and activator of transcription 1 (STAT-1) is involved in the mechanism of oxidative/nitrosative stress. We investigated whether acetylcholine (ACh) generates oxidative/nitrosative stress in bronchial epithelial cells during airway inflammation of COPD and evaluated the effects of Tiotropium, a once-daily antimuscarinic drug, and Olodaterol, a long-acting β2-agonist on these mechanisms. Human bronchial epithelial cells (16-HBE) were stimulated (4h, 37°C) with induced sputum supernatants (ISSs) from healthy controls (HC) (n=10), healthy smokers (HS) (n=10) or COPD patients (n=10), as well as with ACh (f…

Malemedicine.medical_specialtyBlotting WesternNitric Oxide Synthase Type IIBronchiOxidative phosphorylationCholinergic AgonistsFlow cytometrychemistry.chemical_compoundPulmonary Disease Chronic ObstructiveWestern blotInternal medicinemedicineHumansRNA Small InterferingMolecular BiologyCells Culturedchemistry.chemical_classificationReactive oxygen speciesbiologymedicine.diagnostic_testNitrotyrosineEpithelial CellsMiddle AgedAcetylcholinerespiratory tract diseasesEpithelial cellNitric oxide synthaseOxidative StressEndocrinologySTAT1 Transcription FactorchemistrySTAT proteinbiology.proteinOxidative/nitrosative stressTyrosineMolecular MedicineSTAT-1FemaleReactive Oxygen SpeciesAcetylcholinemedicine.drugBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
researchProduct